3-Imidazol-1-yl-2-oxopropanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Imidazol-1-yl-2-oxopropanoic acid
• 化学式: C₆H₆N₂O₃
• 分子量: 154.12
• InChiKey: TZKAUGKXAWURCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Alpha keto acid compositions for treating hypo-albuminemia
  申请人：Hull, Jr. Edgar L.

  公开号：US11253496B2

  公开（公告）日：2022-02-22

  Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium salt and/or the calcium salt of the alpha keto acids of: α-leucine, α-valine, α-isoleucine, α-phenylalanine, α-hydroxy methionine; and/or α-tryptophan, and/or α-tyrosine; 2) L-lysine monoacetate, L-threonine; and/or 3) histidine, tryptophan, and tyrosine, as amino acids or base acids. The specific formulation administered depends in part upon which stage 2-5 of renal disease the patient has. The invention further comprises methods of treatment of disorders associated with low serum albumin using the composition as an over-the-counter pill. The patient's serum albumin is tested on a periodic basis and the selected composition and dose are adjusted accordingly. And the invention comprises method of making α-leucine, α-valine, α-isoleucine, a-tyrosine and α-tryptophan in a multi-step process.

  本文提供了主要用于治疗患有低血清白蛋白的肾病患者的营养或治疗组合物和方法。这些组合物分为四种配方，包括1）α-亮氨酸、α-缬氨酸、α-异亮氨酸、α-苯丙氨酸、α-羟基蛋氨酸的α-酮酸的镁盐和/或钙盐；和/或α-色氨酸和/或α-酪氨酸；2）L-赖氨酸单乙酸酯、L-苏氨酸；和/或3）组氨酸、色氨酸和酪氨酸，作为氨基酸或碱酸。施用的特定制剂部分取决于患者肾病的 2-5 期。本发明还包括使用该组合物作为非处方药丸治疗与低血清白蛋白有关的疾病的方法。定期检测患者的血清白蛋白，并相应调整所选组合物和剂量。本发明还包括通过多步骤工艺制造α-亮氨酸、α-缬氨酸、α-异亮氨酸、a-酪氨酸和α-色氨酸的方法。
• Alpha Keto Acid Compositions for Treating Hypo-Albuminemia
  申请人：Hull, JR. Edgar L.

  公开号：US20200281881A1

  公开（公告）日：2020-09-10

  Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium salt and/or the calcium salt of the alpha keto acids of: α-leucine, α-valine, α-isoleucine, α-phenylalanine, α-hydroxy methionine; and/or α-tryptophan, and/or α-tyrosine; 2) L-lysine monoacetate, L-threonine; and/or 3) histidine, tryptophan, and tyrosine, as amino acids or base acids. The specific formulation administered depends in part upon which stage 2-5 of renal disease the patient has. The invention further comprises methods of treatment of disorders associated with low serum albumin using the composition as an over-the-counter pill. The patient's serum albumin is tested on a periodic basis and the selected composition and dose are adjusted accordingly. And the invention comprises method of making α-leucine, α-valine, α-isoleucine, a-tyrosine and α-tryptophan in a multi-step process.
• Method of Making a Magnesium Salt of an Alpha Keto Acid of Leucine, Isoleucine, and Valine
  申请人：Hull, JR. Edgar L.

  公开号：US20220133667A1

  公开（公告）日：2022-05-05

  A method of making a magnesium salt of an alpha keto acid of the amino acid comprising valine, leucine, and/or isoleucine: 1) combining ingredients comprising: a calcium salt of an amino acid valine, leucine, or isoleucine; water; hydrochloric acid; and methyl tert-butyl ether; 2) stirring for about thirty minutes; 3) allowing the composition to settle into two layers, and collecting the top organic layer, and adding water and magnesium carbonate to the top organic layer; 4) heating the composition for one hour to 60-65° Celsius; 5) removing the solvent, cooling, and adding methyl-tert-butyl ether; 6) stirring the composition for one hour at 25-30° Celsius; 7) filtering, washing, drying under vacuum, and storing the composition as a powder; and 8) wherein the powder is a safe consumable low nitrogen product orally administered within a food, a beverage, or a tablet to treat kidney disease.